Compare Marvell Technology Inc (MRVL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Repligen Corporation Common Stock — how do they compare? Marvell Technology Inc trades at $239.36 (market cap $220.43B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Marvell Technology Inc is far larger — about 19.5× Repligen Corporation Common Stock's market cap, and Marvell Technology Inc pays a 0.1% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 43 Days and Repligen Corporation Common Stock for 0 Days on average.
| MRVL | RGEN | |
|---|---|---|
Market Cap | $220.43B | $11.31B |
Volume | 25,874,039 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $316.43 | $194.57 |
52-Week Low | $73.73 | $102.87 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $221.79B | $11.20B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $268.73, up 1.08% today, with a bullish technical signal from moving averages and strong analyst support. The company reported three consecutive quarterly EPS beats and projects robust revenue growth, driven by AI and data center demand. Recent news highlights a $120 billion potential deal with Google and raised fiscal 2028 guidance to $18 billion, fueling investor optimism despite high valuation multiples.
Outlook remains positive with a consensus price target of $327.86, implying 22% upside, but risks include elevated P/E of 88.98 and dependence on hyperscaler contracts. Net losses in 2025 contrast with projected 2026 profitability, requiring execution on custom chip growth to justify valuations amid competitive pressures.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
